Subject-Relevant Outcomes of On-Label 50 U AbobotulinumtoxinA Treatment for Moderate-to-Severe Glabellar Lines Across Three Individual Trials. (July 2022) - Moradi, Amir; Cox, Sue Ellen; Glaser, Dee Anna; Dayan, Steven; Jacob, Carolyn; Schlessinger, Joel; Joseph, John; Andriopoulos, Bill